We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Yhb5.0

Yohimbine Research

Mostly mechanism / observational

46 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Yohimbine studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from high-quality meta-analyses and randomised trials published 1981–2025 with a typical study size of 41 participants.

Based on 46 studies · 3 meta-analyses · 37 RCTs · 306 total participants

Confidence

High confidence

By outcome

Erectile function & male vitalityModerate improvement in erectile function vs placebo, clearest when combined with other agents · 2-8 weeks · Raises sympathetic/noradrenergic tone and supports erectile function; not a testosterone or hormone modulator per se · 2-8 weeks
Mostly mechanism / observational11 studies
Anxiety & stress
Mostly mechanism / observational4 studies
Fat loss & body compositionModest fat mobilization (best fasted, in stubborn depots); a small RCT showed ~2% lower body fat over 3 weeks · 3-8 weeks
Mostly mechanism / observational3 studies
Heart & blood pressure
Mostly mechanism / observational3 studies
Safety profile
Too few graded studies2 studies
Endurance & exercise performanceUsed as a pre-workout stimulant; no demonstrated improvement in strength, power, or performance markers · 30-60 minutes (acute)
Too few graded studies1 study

Steady research

6 studies in the last 5 years · Latest meta-analysis: 2021

198120032025

1Meta-Analysis1996

Carey MP, Johnson BT · Arch Sex Behav (1996)

Yohimbine Research

Mostly mechanism / observational

Effectiveness of yohimbine in the treatment of erectile disorder: four meta-analytic integrations.

Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials.

Enhancement of exposure therapy in participants with specific phobia: A randomized controlled trial comparing yohimbine, propranolol and placebo.

Effect of clonidine and yohimbine on sleep in man: polygraphic study and EEG analysis by normalized slope descriptors.

Efficacy and safety of a novel combination of L-arginine glutamate and yohimbine hydrochloride: a new oral therapy for erectile dysfunction.

Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial.

Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure.

Effect of 3 weeks treatment with yohimbine on salivary secretion in healthy volunteers and in depressed patients treated with tricyclic antidepressants.

Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response.

A randomized crossover study using yohimbine and isoxsuprine versus pentoxifylline in the management of vasculogenic impotence.

Desipramine-yohimbine combination treatment of refractory depression. Implications for the beta-adrenergic receptor hypothesis of antidepressant action.

Effect of yohimbine-trazodone on psychogenic impotence: a randomized, double-blind, placebo-controlled study.

Favourable effects of yohimbine on clomipramine-induced orthostatic hypotension: a double-blind study.

Mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: a randomized, placebo controlled trial.

Yohimbine does not affect fat distribution in men.

Augmenting treatment efficiency in exposure therapy for PTSD: a randomized double-blind placebo-controlled trial of yohimbine HCl.

The alpha-2 adrenoceptor antagonist yohimbine does not facilitate weight loss but blocks adrenaline induced platelet aggregation in obese subjects.

Yohimbine augmentation of fluvoxamine in refractory depression: a single-blind study.

Plasma MHPG response to yohimbine treatment in women with hypoactive sexual desire.

Synergistic effect of norepinephrine transporter blockade and α-2 antagonism on blood pressure in autonomic failure.